The Aurora B and CSF1R interaction also explained the antagonism between midostaurin and motesanib, consistent with its role in breast cancer development.36 The successful model predictions for experimentally-validated drug combinations and their target interactions exemplified the rationale of leveraging polypharmacology data and network modeling to identify cell-specific drug combinations. The gene discussed is AURKB; the disease is breast cancer.